Category: Redefining Every Stage Investments (RESI)
The Redefining Every Stage Investments (RESI) Conference is an ongoing conference series that provides an international venue for life science companies across Biotech, Medtech, Diagnostics and Healthcare IT and to source investors from around the globe, create relationships, and eventually, secure funding.
On April 4, 2017, The Redefining Early Stage Investments (RESI) Conference will be back to Toronto’s MaRS Discovery District, the home of notable life science organizations including JLABS@Toronto, the Ontario Institute for Cancer Research, Synaptive Medical, and LEAGUE. RESI on MaRS will bring together fundraising CEOs and early stage investors from around the globe, providing the opportunity for dialogue and relationship building, with the goal of eventual capital allocations.
What to expect numbers
Don’t miss the opportunity to attend the 12th RESI conference where you will speak one-on-one with active investors, establish strategic partnerships, learn from the 20 in-depth panels featuring investors across 10 categories (Family Offices, Corporate Venture Funds, Angel Groups, Venture Philanthropy, Venture Capital and more) and find collaborators for licensing and research.
RESI @ JPM has generated feedback from a wide swath of attendees thus far. What LSN has heard has been two quite distinctive words: “Crazy good.” An interesting mantra, and it’s right on.
The overriding response was that the RESI conference is not stale (same old talking heads for decades) or burdened with a sterile-like quality of private white meeting rooms. RESI is not the “quiet car,” and most certainly is not projecting a low energy library-like atmosphere.
On the contrary, when you step into the beehive of RESI and into its palatable energy and buzzing noise, you know it’s different. It’s not only for the elite phase III and commercialization cadre that play in the later stage life science arena.
The RESI conference series is the Wild West of the life science arena, with preclinical and early stage players not looking to be catered to with pomp and circumstance – actually just the opposite. The game is afoot – let’s engage in the hunt for assets! Send forth the hounds, blow the trumpets, let’s make some noise!
Packed into an eclectic 12-story Spanish Colonial-style building built in 1926, RESI attendees were walking up and down tight flights of stairs to get around the crowd, but many seemed to know the drill – it was the third RESI @ JPM event.
And the RESI vibe brings down the walls and barriers and everybody is talking and meeting; it’s just a really open and accepting crowd.
The real win is that the attendees are the who’s who of global early stage investment. Savvy fundraising CEOs are smart enough to figure it out, and booked up to 16 meetings with investors that fit their stage and product – not to mention the additional ad hoc meetings that are the hallmark of the event.
There is a tribe of players, both global early stage investors and startup CEOs, that follow the RESI conference throughout the year. In 2017 there will be 5 RESI events through out North America: San Francisco, Toronto, San Diego, Boston and New York.
RESI is happening and capital is flowing into the drug, device, diagnostic and health IT startups. We hear about the resulting allocations almost every week.
As RESI attracts increasing media attention, BioWorld have provided some highlights and analysis on RESI’s content. This roundup focuses on two of RESI’s investor panels: Biotech Angels and Tales From The Road. Between these two sessions, RESI attendees caught a high-level view inside an early stage life science deal from both sides. On one side of the table, angel investors explore how they hunt for deals and work with startups after investment. On the other side, successful CEOs share their stories of finding and vetting investors who are a fit for their companies. You can read more at BioWorld: http://www.bioworld.com/content/know-your-investors-and-live-your-business-plan
Shaoyu Chang, MD, MPH, Director of Research & Asia Business Development Liaison
The third RESI San Francisco Conference event, held on January 10th, saw 30 Innovation Challenge finalists competing for the votes of the largest RESI crowd to date. With 1,000 attendees present, more votes were cast than in any Innovation Challenge to date. Biotech, medical device, diagnostic and digital health companies all competed in the exhibition-style challenge for the top prize. Selected from over 100 applicants, the 30 finalists included many phenomenal startups. Here, LSN would like to present the 3 winners.
First Place: Pathcore (Toronto, Canada)
Pathcore brings innovation to the crossroads of pathology and computation. By leveraging the power of digital computing and algorithm-based image analysis, digital pathology has the potential to transform healthcare. Pathology is essential to the diagnosis and treatment of cancer and other diseases, as well as the discovery and evaluation of new treatments. Hundreds of millions of dollars are spent on cancer research every year, and Pathcore is focused on providing the tools to accelerate that research and translate it into applied solutions. Pathcore is committed to pathologists and the patients they serve. Our software solutions are designed by pathologists, for pathologists, to enable them to work together, share their knowledge and expertise, and be more accurate, effective, and efficient.
Michael Quigley, VP of Market Research, Life Science Nation | Dan Hosseinzadeh, CEO, Pathcore | George Ayd Assistant Vice President, Medmarc | Stephane Langevin, CCO, Pathcore
Second Place: Myndblue (Cambridge, MA)
MyndBlue is a digital health/ connected medical device that detects and monitors relapse/recurrence in Major Depressive Disorders and Chronic PTSD. The company is headquartered in Paris and has US office in Cambridge, MA. MyndBlue’s mission is to change the way mental health conditions are diagnosed through technology, data and design – to get patients the right care. Mental health conditions affect around 615 million people worldwide. MyndBlue’s remote monitoring platform allows for a patient to be monitored with a proprietary device to provide information to a clinician before a crisis.
Michael Quigley, VP of Market Research, Life Science Nation | Denis Fompeyrine, PhD Founder & CEO, Myndblue | Nancy Briefs Serial Medical/Digital Health Entrepreneur, Myndblue | George Ayd Assistant Vice President, Medmarc
Third Place: Propep Surgical (Austin, TX)
Sexual dysfunction and urinary incontinence are both common side effects following prostate cancer surgery. Inadvertent nerve injury occurring during the surgery is believed to be one of the primary causes. Using nerve monitoring technology that has been the Standard of Care in multiple surgical procedures for over 20 years, the ProPep® Nerve Monitoring System brings the same instant and accurate information regarding nerve location and function to laparoscopic and robotic prostatectomy surgery for the first time ever. The ProPep® Nerve Monitoring System is the first FDA-cleared real-time nerve monitoring system for laparoscopic & robotic prostatectomy surgery. With over 2500 commercial cases completed this system is proven to help surgeons identify critical non-visible somatic nerves at risk during surgery, thereby allowing the surgeon to make more-informed decisions on how to spare these nerves, potentially minimizing nerve damage.
Thank you to all who competed in the RESI San Francisco Innovation Challenge, and to all the RESI attendees who took part by investing their votes in their favorite competing companies.
LSN is looking forward to hosting the 11th Redefining Early Stage Investments Conference (RESI) during San Francisco’s annual healthcare conference week. At RESI, over 450 investors will be under one roof in search of compelling connections with early stage companies.
LSN would like to present the RESI San Francisco 2017 Program Guide. If you’re planning your day at RESI SF and want to see full lists of the investor panel speakers, RESI Innovation Challenge finalists and service providers you could meet, look no further!
Throughout 2016, Next Phase has brought you updates and advice on early stage life science fundraising. This week, we’d like to take a look back at the highlights of the year, from some hard data on drug development funding to tips on marketing and pitching your company. We hope you enjoy this roundup of our top 10 articles of the year. See you in 2017.
Large technology companies have been expanding their footprint in the healthcare sector through venture investment and partnerships into early stage healthcare companies. Often seeking technology with a significant software component, many of these groups have helped to fuel the massive growth that has been seen in the digital health space in the past few years. From patient monitoring devices to mobile 3D imaging devices the lines between pure tech and healthcare are slowly beginning to blur as healthcare providers continually look to improve care while lowering costs.
Moderated by Michael Greeley, General Partner, Flare Capital Partners, the panelists are:
Iana Dimkova, Senior Associate, Healthcare, GE Ventures
Lucian Iancovici, FACHE, Head of Qualcomm Life Fund, Qualcomm Ventures
Ying Tam, Head, Digital Health Cluster, Venture Services, MaRS
In this session, a number of investors at these large firms will discuss their involvement in healthcare innovation ecosystem. What types of technologies they are interested in? How much data do they like to see pre-investment? What problems in the space are they looking to tackle? These questions and more will be answered at RESI on Jan 10th so if you’re looking to partner with a large tech company for your product this is a panel you don’t want to miss.
